Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers

被引：1
|
作者：
Lee, D [1 ]
Han, J [1 ]
Lee, E [1 ]
Kim, H [1 ]
Kim, H [1 ]
Hong, E [1 ]
Lee, J [1 ]
机构：
[1] Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80242-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [1] Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers
    Lee, DH
    Han, JY
    Lee, HG
    Lee, JJ
    Lee, EK
    Kim, HY
    Kim, HK
    Hong, EK
    Lee, JS
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (08) : 3032 - 3037
  • [2] The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: A prospective study
    Lee, Dae Ho
    Han, Ji-Youn
    Yu, Sun Young
    Kim, Hyae Young
    Nam, Byung-Ho
    Hong, Eun Kyung
    Kim, Heung Tae
    Lee, Jin Soo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (09) : 965 - 971
  • [3] A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung
    Lee, Jin S.
    Park, Keunchil
    Kim, Sang-We
    Lee, Dae Ho
    Kim, Heung Tae
    Han, Ji-Youn
    Yun, Tak
    Ahn, Myung-Ju
    Ahn, Jin Seok
    Suh, Cheolwon
    Lee, Jung-Shin
    Han, Jong Hee
    Yu, Sun Young
    Lee, Jae Won
    Jo, SookJung
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S283 - S284
  • [4] Association of XRCC1 Arg399GIn polymorphism with tumor response and survival in never-smokers with advanced lung adenocarcinoma treated with gefitinib as the first-line therapy
    Han, Ji-Youn
    Yoon, Kyong-Ah
    Park, Jae Hee
    Yoon, Sung Jin
    Han, Jong Hee
    Lee, Jin Soo
    [J]. CANCER RESEARCH, 2009, 69
  • [5] Association of XRCC1 Arg399Gln polymorphism with tumor response and survival in never-smokers with advanced lung adenocarcinoma treated with gefitinib as the first-line therapy
    Han, Ji-Youn
    Yoon, Kyong-Ah
    Park, Jae Hee
    Yoon, Sung Jin
    Han, Jong Hee
    Lee, Jin Soo
    [J]. CANCER RESEARCH, 2009, 69
  • [6] Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy
    Lee, Young Joo
    Yoon, Kyong-Ah
    Han, Ji-Youn
    Kim, Heung Tae
    Yun, Tak
    Lee, Geon Kook
    Kim, Hyae Young
    Lee, Jin Soo
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (15) : 5179 - 5187
  • [7] Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as a first-line therapy
    Lee, Young Joo
    Yoon, Kyong-Ah
    Lee, Jin Soo
    [J]. CANCER RESEARCH, 2011, 71
  • [8] DNA Repair Gene Polymorphisms and Benefit From Gefitinib in Never-Smokers With Lung Adenocarcinoma
    Han, Ji-Youn
    Yoon, Kyong-Ah
    Park, Jae Hee
    Lee, Young Joo
    Lee, Geon Kook
    Han, Jong Hee
    Yoon, Sung Jin
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    [J]. CANCER, 2011, 117 (14) : 3201 - 3208
  • [9] Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy
    Lee, Youngjoo
    Kim, Sun Hye
    Han, Ji-Youn
    Kim, Heung Tae
    Yun, Tak
    Lee, Jin Soo
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (12) : 2009 - 2016
  • [10] Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy
    Youngjoo Lee
    Sun Hye Kim
    Ji-Youn Han
    Heung Tae Kim
    Tak Yun
    Jin Soo Lee
    [J]. Journal of Cancer Research and Clinical Oncology, 2012, 138 : 2009 - 2016
12345